So long, Shulkin? Trump eyes Cleveland Clinic’s Cosgrove as VA sec

Conflicting news reports swirl around David Shulkin, Veterans Affairs Secretary to President Donald Trump who has faced criticism for excessive travel spending and heavy-handed approaches to staffing decisions.

On Monday, March 26, the AP released a story citing White House sources who expected Shulkin to be removed in the coming days. One unnamed source guessed the VA Secretary had a 50-50 chance of surviving the next few days. By the end of the day, contradicting reports emerged. Politico published a story that President Trump had confidence in Shulkin “at this time”—a phrase that could be considered ominous in an administration known for its turnover.

Additional reports state former Cleveland Clinic CEO Tony Cosgrove is a leading figure to replace Shulkin, should be he ousted. According to Cleveland.com, he has not had discussions with the White House about such a move.

He has been linked to the VA before—with Barack Obama offering him the job in 2014 and Trump discussing it in 2017. Cosgrove turned down the opportunity both times.

"Dr. Cosgrove was honored to be considered for the role, but withdrew his name because of commitments he has yet to fulfill here at Cleveland Clinic," Clinic spokeswoman Eileen Sheil said after Cosgrove stepped out of the running in 2017. "It was a difficult decision that he did not take lightly. As a Vietnam Veteran, he understands the importance of this role."

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.